1-19 of 19
Francis Giles
Close
Save search
Follow your search
Access your saved searches in your account
Would you like to receive an alert when new items match your search?
Close Modal
Sort by
Journal Articles

Leukemic Stem Cell Quantification in Newly Diagnosed Patients With Chronic Myeloid Leukemia Predicts Response to Nilotinib Therapy

Noortje Thielen, Johan Richter, Matthias Baldauf, Gisela Barbany, Thoas Fioretos, Francis Giles, Bjørn-Tore Gjertsen, Andreas Hochhaus, Gerrit Jan Schuurhuis, Sieghart Sopper, Leif Stenke, Sarah Thunberg, Dominik Wolf, Gert Ossenkoppele, Kimmo Porkka, Jeroen Janssen, Satu Mustjoki
Journal: Clinical Cancer Research
Clin Cancer Res (2016) 22 (16): 4030–4038.
https://doi.org/10.1158/1078-0432.CCR-15-2791
Published: 14 August 2016
View article titled, Leukemic Stem Cell Quantification in Newly Diagnosed Patients With Chronic Myeloid Leukemia Predicts Response to Nilotinib Therapy
Open the PDF for Leukemic Stem Cell Quantification in Newly Diagnosed Patients With Chronic Myeloid Leukemia Predicts Response to Nilotinib Therapy in another window
Includes: Supplementary data
Journal Articles

Enzymatic activity of free circulating proteasomes as biomarkers for predicting clinical behavior in hematologic diseases

Maher Albitar, Wanlong Ma, Susan O'Brien, Iman Jilani, Xi Zhang, Hagop Kantarjian, Zeev Estrov, Michael Keating, Francis Giles
Journal: Clinical Cancer Research
Clin Cancer Res (2007) 13 (19_Supplement): B52.
Published: 15 August 2014
View article titled, Enzymatic activity of free circulating proteasomes as biomarkers for predicting clinical behavior in hematologic diseases
Journal Articles

BCR-ABL alternative-splicing as a common mechanism for Imatinib resistance: Evidence from molecular dynamics simulations

Wanlong Ma, Tai-Sung Lee, Xi Zhang, Geoge Cortes, Francis Giles, Hagop Kantarjian, Maher Albitar
Journal: Clinical Cancer Research
Clin Cancer Res (2008) 14 (15_Supplement): B31.
Published: 15 August 2014
View article titled, BCR-ABL alternative-splicing as a common mechanism for Imatinib resistance: Evidence from molecular dynamics simulations
Journal Articles

Plasma is more sensitive than cellular analysis for detecting JAK2 mutations and determining zygosity

Maher Albitar, Wanlong Ma, Xi Zhang, Iman Jilani, Hagop Kantarjian, Francis Giles
Journal: Clinical Cancer Research
Clin Cancer Res (2007) 13 (19_Supplement): B53.
Published: 15 August 2014
View article titled, Plasma is more sensitive than cellular analysis for detecting <em>JAK2</em> mutations and determining zygosity
Journal Articles

Circulating Ki-67 protein as a biomarker and prognostic indicator of acute lymphoblastic leukemia

Jean-Marie Bruey, Hagop Kantarjian, Wanlong Ma, Deborah Thomas, Francis Giles, Maher Albitar
Journal: Clinical Cancer Research
Clin Cancer Res (2008) 14 (19_Supplement): B36.
Published: 15 August 2014
View article titled, Circulating Ki-67 protein as a biomarker and prognostic indicator of acute lymphoblastic leukemia
Journal Articles

Proteasome Enzymatic Activities in Plasma as Risk Stratification of Patients with Acute Myeloid Leukemia and Advanced-Stage Myelodysplastic Syndrome

Wanlong Ma, Hagop Kantarjian, Benjamin Bekele, Amber C. Donahue, Xi Zhang, Zhong J. Zhang, Susan O'Brien, Elihu Estey, Zeev Estrov, Jorge Cortes, Michael Keating, Francis Giles, Maher Albitar
Journal: Clinical Cancer Research
Clin Cancer Res (2009) 15 (11): 3820–3826.
https://doi.org/10.1158/1078-0432.CCR-08-3034
Published: 01 June 2009
View article titled, Proteasome Enzymatic Activities in Plasma as Risk Stratification of Patients with Acute Myeloid Leukemia and Advanced-Stage Myelodysplastic Syndrome
Open the PDF for Proteasome Enzymatic Activities in Plasma as Risk Stratification of Patients with Acute Myeloid Leukemia and Advanced-Stage Myelodysplastic Syndrome in another window
Includes: Supplementary data
Journal Articles

A Phase I Study of the Pan Bcl-2 Family Inhibitor Obatoclax Mesylate in Patients with Advanced Hematologic Malignancies

Aaron D. Schimmer, Susan O'Brien, Hagop Kantarjian, Joseph Brandwein, Bruce D. Cheson, Mark D. Minden, Karen Yee, Farhad Ravandi, Francis Giles, Andre Schuh, Vikas Gupta, Michael Andreeff, Charles Koller, Hong Chang, Suzanne Kamel-Reid, Mark Berger, Jean Viallet, Gautam Borthakur
Journal: Clinical Cancer Research
Clin Cancer Res (2008) 14 (24): 8295–8301.
https://doi.org/10.1158/1078-0432.CCR-08-0999
Published: 15 December 2008
View article titled, A Phase I Study of the Pan Bcl-2 Family Inhibitor Obatoclax Mesylate in Patients with Advanced Hematologic Malignancies
Open the PDF for A Phase I Study of the Pan Bcl-2 Family Inhibitor Obatoclax Mesylate in Patients with Advanced Hematologic Malignancies in another window
Journal Articles

Important Therapeutic Targets in Chronic Myelogenous Leukemia

Hagop M. Kantarjian, Francis Giles, Alfonso Quintás-Cardama, Jorge Cortes
Journal: Clinical Cancer Research
Clin Cancer Res (2007) 13 (4): 1089–1097.
https://doi.org/10.1158/1078-0432.CCR-06-2147
Published: 22 February 2007
View article titled, Important Therapeutic Targets in Chronic Myelogenous Leukemia
Open the PDF for Important Therapeutic Targets in Chronic Myelogenous Leukemia in another window
Journal Articles

A Phase I Study of Intravenous LBH589, a Novel Cinnamic Hydroxamic Acid Analogue Histone Deacetylase Inhibitor, in Patients with Refractory Hematologic Malignancies

Francis Giles, Thomas Fischer, Jorge Cortes, Guillermo Garcia-Manero, Joachim Beck, Farhad Ravandi, Eric Masson, Patricia Rae, Glen Laird, Sunil Sharma, Hagop Kantarjian, Margaret Dugan, Maher Albitar, Kapil Bhalla
Journal: Clinical Cancer Research
Clin Cancer Res (2006) 12 (15): 4628–4635.
https://doi.org/10.1158/1078-0432.CCR-06-0511
Published: 09 August 2006
View article titled, A Phase I Study of Intravenous LBH589, a Novel Cinnamic Hydroxamic Acid Analogue Histone Deacetylase Inhibitor, in Patients with Refractory Hematologic Malignancies
Open the PDF for A Phase I Study of Intravenous LBH589, a Novel Cinnamic Hydroxamic Acid Analogue Histone Deacetylase Inhibitor, in Patients with Refractory Hematologic Malignancies in another window
Journal Articles

Population Pharmacokinetics of Troxacitabine, a Novel Dioxolane Nucleoside Analogue

Carlton K. K. Lee, Eric K. Rowinsky, Jing Li, Francis Giles, Malcolm J. Moore, Manuel Hidalgo, Edmund Capparelli, Jacques Jolivet, Sharyn D. Baker
Journal: Clinical Cancer Research
Clin Cancer Res (2006) 12 (7): 2158–2165.
https://doi.org/10.1158/1078-0432.CCR-05-2249
Published: 11 April 2006
View article titled, Population Pharmacokinetics of Troxacitabine, a Novel Dioxolane Nucleoside Analogue
Open the PDF for Population Pharmacokinetics of Troxacitabine, a Novel Dioxolane Nucleoside Analogue in another window
Journal Articles

Phase I Study of Cloretazine (VNP40101M), a Novel Sulfonylhydrazine Alkylating Agent, Combined with Cytarabine in Patients with Refractory Leukemia

Francis Giles, Srdan Verstovsek, Deborah Thomas, Stanton Gerson, Jorge Cortes, Stefan Faderl, Alessandra Ferrajoli, Farhad Ravandi, Steven Kornblau, Guillermo Garcia-Manero, Elias Jabbour, Susan O'Brien, Verena Karsten, Ann Cahill, Karen Yee, Maher Albitar, Mario Sznol, Hagop Kantarjian
Journal: Clinical Cancer Research
Clin Cancer Res (2005) 11 (21): 7817–7824.
https://doi.org/10.1158/1078-0432.CCR-05-1070
Published: 08 November 2005
View article titled, Phase I Study of Cloretazine (VNP40101M), a Novel Sulfonylhydrazine Alkylating Agent, Combined with Cytarabine in Patients with Refractory Leukemia
Open the PDF for Phase I Study of Cloretazine (VNP40101M), a Novel Sulfonylhydrazine Alkylating Agent, Combined with Cytarabine in Patients with Refractory Leukemia in another window
Journal Articles

AMN107, a Novel Aminopyrimidine Inhibitor of Bcr-Abl, Has In vitro Activity against Imatinib-Resistant Chronic Myeloid Leukemia

Mirna Golemovic, Srdan Verstovsek, Francis Giles, Jorge Cortes, Taghi Manshouri, Paul W. Manley, Jürgen Mestan, Margaret Dugan, Leila Alland, James D. Griffin, Ralph B. Arlinghaus, Tong Sun, Hagop Kantarjian, Miloslav Beran
Journal: Clinical Cancer Research
Clin Cancer Res (2005) 11 (13): 4941–4947.
https://doi.org/10.1158/1078-0432.CCR-04-2601
Published: 06 July 2005
View article titled, AMN107, a Novel Aminopyrimidine Inhibitor of Bcr-Abl, Has <em>In vitro</em> Activity against Imatinib-Resistant Chronic Myeloid Leukemia
Open the PDF for AMN107, a Novel Aminopyrimidine Inhibitor of Bcr-Abl, Has <em>In vitro</em> Activity against Imatinib-Resistant Chronic Myeloid Leukemia in another window
Journal Articles

Molecular Responses in Patients with Chronic Myelogenous Leukemia in Chronic Phase Treated with Imatinib Mesylate

Jorge Cortes, Moshe Talpaz, Susan O'Brien, Dan Jones, Rajyalakshmi Luthra, Jenny Shan, Francis Giles, Stefan Faderl, Srdan Verstovsek, Guillermo Garcia-Manero, Mary B. Rios, Hagop Kantarjian
Journal: Clinical Cancer Research
Clin Cancer Res (2005) 11 (9): 3425–3432.
https://doi.org/10.1158/1078-0432.CCR-04-2139
Published: 02 May 2005
View article titled, Molecular Responses in Patients with Chronic Myelogenous Leukemia in Chronic Phase Treated with Imatinib Mesylate
Open the PDF for Molecular Responses in Patients with Chronic Myelogenous Leukemia in Chronic Phase Treated with Imatinib Mesylate in another window
Journal Articles

Phase I Study of Bortezomib in Refractory or Relapsed Acute Leukemias

Jorge Cortes, Deborah Thomas, Charles Koller, Francis Giles, Elihu Estey, Stefan Faderl, Guillermo Garcia-Manero, David McConkey, Gira Patel, Roberto Guerciolini, John Wright, Hagop Kantarjian
Journal: Clinical Cancer Research
Clin Cancer Res (2004) 10 (10): 3371–3376.
https://doi.org/10.1158/1078-0432.CCR-03-0508
Published: 24 May 2004
View article titled, Phase I Study of Bortezomib in Refractory or Relapsed Acute Leukemias
Open the PDF for Phase I Study of Bortezomib in Refractory or Relapsed Acute Leukemias in another window
Journal Articles

A Phase I and Pharmacokinetic Study of VNP40101M, a Novel Sulfonylhydrazine Alkylating Agent, in Patients with Refractory Leukemia

Francis Giles, Deborah Thomas, Guillermo Garcia-Manero, Stefan Faderl, Jorge Cortes, Srdan Verstovsek, Alessandra Ferrajoli, Sima Jeha, Miloslav Beran, Charles Koller, Michael Andreeff, Ann Cahill, Caroline Clairmont, Mario Sznol, Hagop Kantarjian
Journal: Clinical Cancer Research
Clin Cancer Res (2004) 10 (9): 2908–2917.
https://doi.org/10.1158/1078-0432.CCR-03-0738
Published: 06 May 2004
View article titled, A Phase I and Pharmacokinetic Study of VNP40101M, a Novel Sulfonylhydrazine Alkylating Agent, in Patients with Refractory Leukemia
Open the PDF for A Phase I and Pharmacokinetic Study of VNP40101M, a Novel Sulfonylhydrazine Alkylating Agent, in Patients with Refractory Leukemia in another window
Journal Articles

Survival Advantage with Imatinib Mesylate Therapy in Chronic-Phase Chronic Myelogenous Leukemia (CML-CP) after IFN-α Failure and in Late CML-CP, Comparison with Historical Controls

Hagop Kantarjian, Susan O’Brien, Jorge Cortes, Francis Giles, Jianqin Shan, Mary Beth Rios, Stefan Faderl, Srdan Verstovsek, Guillermo Garcia-Manero, William Wierda, Steven Kornblau, Alessandra Ferrajoli, Michael Keating, Moshe Talpaz
Journal: Clinical Cancer Research
Clin Cancer Res (2004) 10 (1): 68–75.
https://doi.org/10.1158/1078-0432.CCR-1035-3
Published: 20 January 2004
View article titled, Survival Advantage with Imatinib Mesylate Therapy in Chronic-Phase Chronic Myelogenous Leukemia (CML-CP) after IFN-α Failure and in Late CML-CP, Comparison with Historical Controls
Open the PDF for Survival Advantage with Imatinib Mesylate Therapy in Chronic-Phase Chronic Myelogenous Leukemia (CML-CP) after IFN-α Failure and in Late CML-CP, Comparison with Historical Controls in another window
Journal Articles

Phase I Study of Oral Topotecan in Hematological Malignancies

Miloslav Beran, Susan O’Brien, Deborah A. Thomas, Hai T. Tran, Jorge E. Cortes-Franco, Francis Giles, Elihu Estey, Hagop M. Kantarjian
Journal: Clinical Cancer Research
Clin Cancer Res (2003) 9 (11): 4084–4091.
Published: 30 September 2003
View article titled, Phase I Study of Oral Topotecan in Hematological Malignancies
Open the PDF for Phase I Study of Oral Topotecan in Hematological Malignancies in another window
Journal Articles

Quantitative Polymerase Chain Reaction Monitoring of BCR-ABL during Therapy with Imatinib Mesylate (STI571; Gleevec) in Chronic-Phase Chronic Myelogenous Leukemia

Hagop M. Kantarjian, Moshe Talpaz, Jorge Cortes, Susan O’Brien, Stefan Faderl, Deborah Thomas, Francis Giles, Mary Beth Rios, Jianqin Shan, Ralph Arlinghaus
Journal: Clinical Cancer Research
Clin Cancer Res (2003) 9 (1): 160–166.
Published: 01 January 2003
View article titled, Quantitative Polymerase Chain Reaction Monitoring of <em>BCR-ABL</em> during Therapy with Imatinib Mesylate (STI571; Gleevec) in Chronic-Phase Chronic Myelogenous Leukemia
Open the PDF for Quantitative Polymerase Chain Reaction Monitoring of <em>BCR-ABL</em> during Therapy with Imatinib Mesylate (STI571; Gleevec) in Chronic-Phase Chronic Myelogenous Leukemia in another window
Journal Articles

Significance of FHIT Expression in Chronic Myelogenous Leukemia

Hagop M. Kantarjian, Moshe Talpaz, Susan O’Brien, Taghi Manshouri, Jorge Cortes, Francis Giles, Mary Beth Rios, Carlo M. Croce, Maher Albitar
Journal: Clinical Cancer Research
Clin Cancer Res (1999) 5 (12): 4059–4064.
Published: 01 December 1999
View article titled, Significance of FHIT Expression in Chronic Myelogenous Leukemia
Open the PDF for Significance of FHIT Expression in Chronic Myelogenous Leukemia in another window